Drug Combination A new clinical trial demonstrated positive effects caused by the drug combination lapatinib and trastuzumab against HER2 positive breast cancer in a treatment period of just 11 days. Led by researchers at the Institute of Cancer Research, London, the University of Manchester, and University Hospital of South Manchester, the study comprised 257 women with HER2 positive breast cancer who...